Drug Profile
Lebrikizumab companion diagnostic - Roche
Latest Information Update: 29 Sep 2021
Price :
$50
*
At a glance
- Originator Roche
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma
Most Recent Events
- 29 Sep 2021 Phase-III development in Asthma (Diagnosis) is ongoing in USA
- 20 Oct 2016 Phase-III development is ongoing in USA
- 02 Feb 2011 Phase-II clinical trials in Asthma (Diagnosis) in USA (Roche companion diagnostics pipeline, February 2011)